A1ln34 Stock Fundamentals
| A1LN34 Stock | BRL 73.50 0.84 1.16% |
A1LN34 fundamentals help investors to digest information that contributes to A1LN34's financial success or failures. It also enables traders to predict the movement of A1LN34 Stock. The fundamental analysis module provides a way to measure A1LN34's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to A1LN34 stock.
A1LN34 |
A1LN34 Company Current Valuation Analysis
A1LN34's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current A1LN34 Current Valuation | 5.15 B |
Most of A1LN34's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, A1LN34 is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, A1LN34 has a Current Valuation of 5.15 B. This is 64.14% lower than that of the Healthcare sector and 10.86% higher than that of the Biotechnology industry. The current valuation for all Brazil stocks is 69.02% higher than that of the company.
A1LN34 Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining A1LN34's current stock value. Our valuation model uses many indicators to compare A1LN34 value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across A1LN34 competition to find correlations between indicators driving A1LN34's intrinsic value. More Info.A1LN34 is rated below average in return on equity category among its peers. It also is rated below average in return on asset category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value A1LN34 by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for A1LN34's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.A1LN34 Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses A1LN34's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of A1LN34 could also be used in its relative valuation, which is a method of valuing A1LN34 by comparing valuation metrics of similar companies.A1LN34 is currently under evaluation in current valuation category among its peers.
A1LN34 Fundamentals
| Return On Equity | -78.71 | |||
| Return On Asset | -13.65 | |||
| Profit Margin | (128.96) % | |||
| Operating Margin | (109.35) % | |||
| Current Valuation | 5.15 B | |||
| Shares Outstanding | 2.35 B | |||
| Price To Book | 6.22 X | |||
| Price To Sales | 170.35 X | |||
| Revenue | 687.53 M | |||
| Gross Profit | 414.8 M | |||
| EBITDA | (708.47 M) | |||
| Net Income | (886.68 M) | |||
| Cash And Equivalents | 1.9 B | |||
| Cash Per Share | 15.99 X | |||
| Total Debt | 761.07 M | |||
| Debt To Equity | 0.89 % | |||
| Current Ratio | 4.91 X | |||
| Book Value Per Share | 7.89 X | |||
| Cash Flow From Operations | (590.99 M) | |||
| Earnings Per Share | (37.45) X | |||
| Number Of Employees | 1.45 K | |||
| Beta | 1.2 | |||
| Market Capitalization | 117.12 B | |||
| Z Score | 91.8 |
About A1LN34 Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze A1LN34's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of A1LN34 using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of A1LN34 based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing RNA interference therapeutics. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. ALNYLAM PHARDRN operates under Biotechnology classification in Brazil and is traded on Sao Paolo Stock Exchange. It employs 1453 people.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in A1LN34 Stock
A1LN34 financial ratios help investors to determine whether A1LN34 Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in A1LN34 with respect to the benefits of owning A1LN34 security.